Retatrutide vs CagriSema: Next-Gen Weight Loss Medications Compared

Introduction

Two medications are racing toward FDA approval with weight loss results that surpass anything currently available. Retatrutide (Eli Lilly) and CagriSema (Novo Nordisk) represent different approaches to the same goal: achieving weight loss approaching bariatric surgery without the scalpel.

TRIUMPH-4 showed retatrutide achieving 28.7% weight loss at 68 weeks in December 2025. Six months earlier, REDEFINE-1 showed CagriSema achieving 20.4% weight loss at the same timepoint. Both substantially outperform semaglutide's 15%. Both face the same 2027-2028 approval timeline. Both will cost similar amounts.

The difference? Mechanism and magnitude. Retatrutide is a single molecule activating three hormone receptors (GLP-1, GIP, glucagon). CagriSema is two separate molecules—semaglutide (GLP-1 agonist) plus cagrilintide (amylin analog)—combined in one injection. One produces 8 percentage points more weight loss. The other just submitted for FDA approval first.

This comparison examines mechanisms, efficacy data, side effects, approval timelines, and which medication will dominate when both reach market.

The Mechanisms: Triple Agonist vs Dual Combination

Retatrutide: Single Molecule, Three Receptors

Retatrutide is a tri-agonist—one engineered molecule that simultaneously activates three distinct hormone pathways.

GLP-1 Receptor Activation:

• Suppresses appetite through hypothalamic pathways
• Slows gastric emptying
• Enhances insulin secretion

GIP Receptor Activation:

• Amplifies GLP-1 satiety effects
• Improves insulin sensitivity
• May directly affect fat cell metabolism

Glucagon Receptor Activation:

• Increases energy expenditure (metabolic rate)
• Promotes fat breakdown (lipolysis)
• May prevent metabolic adaptation

The Advantage: Single molecule means simpler manufacturing, potentially easier regulatory approval, and all three pathways activated with every dose.

CagriSema: Two Molecules, Complementary Mechanisms

CagriSema combines two existing molecules in a fixed-dose injection.

Semaglutide 2.4mg (GLP-1 Agonist):

• Proven GLP-1 effects (appetite suppression, gastric emptying)
• Already FDA-approved as Wegovy
• Established safety profile

Cagrilintide 2.4mg (Amylin Analog):

• Mimics amylin, a hormone co-secreted with insulin
• Slows gastric emptying through different pathway than GLP-1
• Reduces appetite through hindbrain (not hypothalamus)
• Improves postprandial glucose

The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects. If approved, becomes first GLP-1/amylin combination.

Weight Loss Efficacy: Head-to-Head Comparison

Primary Phase 3 Results

Key Finding: Retatrutide produces 8.3 percentage points more weight loss than CagriSema at 68 weeks.

Real-World Translation

For a 250-pound person:

*Assuming 5'10" height

Difference: Retatrutide loses 21 more pounds than CagriSema.

Percentage Achieving Weight Loss Thresholds

Key Finding: Both medications get most patients past 20% loss. Retatrutide pushes more patients to 25%+.

Trial Design Considerations

REDEFINE-1 Used Flexible Dosing:Investigators could reduce dose if patients experienced intolerable side effects. Only 57% of participants reached the highest 2.4mg/2.4mg dose. This may have reduced average weight loss.

On-Treatment Analysis (If Everyone Stayed on Max Dose):CagriSema achieved 22.7% weight loss using trial-product estimand (assumes perfect adherence at max dose).

TRIUMPH-4 Used Fixed Dosing:All patients in the 12mg group reached 12mg unless they discontinued. This may produce higher average but lower real-world applicability.

Verdict: Direct comparison difficult due to different trial designs, but retatrutide's advantage appears substantial even accounting for flexible vs fixed dosing.

Side Effect Profiles

Gastrointestinal Side Effects

Key Finding: CagriSema had highest overall GI event rate (79.6%). Most were mild-moderate and transient.

Dysesthesia: Retatrutide's Unique Issue

Dysesthesia (abnormal touch sensations) affects 1 in 5 retatrutide patients at highest dose. This side effect doesn't occur with CagriSema or semaglutide.

Discontinuation Rates

*Exact CagriSema discontinuation rate not disclosed in topline results

Both next-gen medications have substantially higher discontinuation than semaglutide alone, reflecting higher side effect burden despite greater efficacy.

Approval Timeline and Availability

CagriSema: Ahead in the Race

FDA Submission: December 18, 2025 (NDA filed)
Expected FDA Decision: Q4 2026 or Q1 2027
Predicted Launch: Mid-2027

Advantage: 6-12 month head start on retatrutide

REDEFINE Program Status:

• REDEFINE-1: ✅ Completed (obesity, 20.4% weight loss)
• REDEFINE-2: ✅ Completed (type 2 diabetes, 13.7% weight loss)
• REDEFINE-3: Ongoing (cardiovascular outcomes trial)
• REDEFINE-8: Ongoing (body composition study)
• High-dose CagriSema (2.4/7.2mg): Starting late 2026

Retatrutide: More Trials Needed

FDA Submission: Expected Q4 2026 or Q1 2027
Expected FDA Decision: Late 2027
Predicted Launch: Q1-Q2 2028

TRIUMPH Program Status:

• TRIUMPH-4: ✅ Completed (osteoarthritis, 28.7% weight loss)
• TRIUMPH-1 & TRIUMPH-2: Expected 2026 (pivotal obesity trials)
• TRIUMPH-5: Expected 2026 (type 2 diabetes)
• TRIUMPH-6: Expected 2026 (sleep apnea)
• TRIUMPH-3: Expected 2026 (cardiovascular disease population)

Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema.

Predicted Pricing and Insurance Coverage

Expected Monthly Costs

Both will be expensive. CagriSema may price slightly higher as "evolution of Wegovy" from Novo Nordisk's established franchise.

Insurance Coverage Predictions

CagriSema (Advantage: Semaglutide Component):

• Leverages Wegovy's established coverage
• "Combination of proven medication + new molecule" easier sell to insurers
• Predicted coverage: 50-60% of commercial plans initially

Retatrutide (Challenge: Novel Molecule):

• Entirely new drug class, no established coverage
• Higher efficacy but also higher side effects
• Will likely require trial-and-failure of cheaper options
• Predicted coverage: 40-50% of commercial plans initially

Clinical Trial Populations and Indications

CagriSema: Diabetes Focus

REDEFINE-1: Obesity without diabetes (3,417 participants)
REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants)
REIMAGINE Program: Additional diabetes-focused trials

Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound).

Retatrutide: Complication Focus

TRIUMPH-4: Obesity + knee osteoarthritis (445 participants)
TRIUMPH-5: Obesity + type 2 diabetes
TRIUMPH-6: Obesity + obstructive sleep apnea

Advantage: Multiple complication-specific trials could lead to broader label (obesity + OA + OSA indications).

Manufacturing and Supply

CagriSema: Combination Product Challenge

Complexity: Two separate molecules in one injection requires complex formulation. Fixed-dose combination means less flexibility in dosing.

Novo Nordisk Experience: Company has struggled with semaglutide supply shortages (Wegovy, Ozempic). Will CagriSema face same issues?

Retatrutide: Single Molecule Advantage

Simplicity: One molecule, potentially simpler manufacturing and quality control.

Eli Lilly Investment: $9 billion in new US manufacturing facilities specifically for obesity medications.

Prediction: Both will face supply constraints at launch, but retatrutide's single-molecule structure may scale faster.

Which Medication Will Win?

CagriSema's Advantages:

✅ First to Market: 6-12 month head start
✅ Leverages Wegovy Success: Built-in brand recognition
✅ Proven Semaglutide Component: Half the drug is already approved
✅ Strong Diabetes Data: Positions for dual indication
✅ No Dysesthesia: Cleaner safety profile in one key area

Retatrutide's Advantages:

✅ Higher Efficacy: 28.7% vs 20.4% (8.3 points more)
✅ Superior BP Reduction: -14 mmHg vs likely similar to semaglutide
✅ Single Molecule: Potentially easier manufacturing
✅ Multiple Indications: OA, OSA, obesity, diabetes trials
✅ Novel Class: First triple agonist = strong IP protection

The Verdict: Market Will Support Both

These medications won't compete head-to-head. They'll serve different niches:

CagriSema Will Dominate:

• Patients familiar with Wegovy brand
• Those wanting proven semaglutide component
• People with type 2 diabetes (strong REIMAGINE data)
• Earlier availability (mid-2027)

Retatrutide Will Dominate:

• Patients needing maximum weight loss (BMI ≥40)
• Those with multiple complications (OA + OSA + obesity)
• People who failed CagriSema
• Willingness to wait for highest efficacy

Tirzepatide (Zepbound) Will Remain Relevant:

• Already available NOW
• Proven safety with 22.5% weight loss
• Lower cost than either new option
• Established insurance coverage

The High-Dose CagriSema Wildcard

Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026—tripling the cagrilintide dose.

Potential Impact:If 2.4mg/2.4mg achieves 20.4% weight loss, could 2.4mg/7.2mg achieve 25-27%? That would narrow the gap with retatrutide substantially.

Risk:Higher cagrilintide dose will likely increase GI side effects and discontinuation rates. May not be tolerable enough for widespread use.

Timeline:High-dose results won't be available until 2028+, well after standard-dose approval. This is a second-generation product.

Conclusion

Retatrutide and CagriSema represent the next generation of obesity pharmacotherapy. Both substantially outperform currently available medications. Both will launch around 2027-2028. Both will cost similar amounts. Both will require prescriptions and prior authorizations.

The 8.3 percentage point efficacy advantage for retatrutide is meaningful—21 pounds difference for a 250-pound person. But CagriSema's 6-12 month head start, proven semaglutide component, and strong diabetes data position it well for first-mover advantage.

Most patients with severe obesity (BMI ≥40) will likely wait for retatrutide's superior efficacy. Patients with BMI 30-40 may prefer CagriSema's earlier availability and cleaner safety profile. The market is large enough to support both medications profitably.

The real question: Will either medication achieve the sustained, widespread use needed to address the global obesity epidemic? Or will high costs, insurance restrictions, side effect burdens, and supply constraints limit them to a small fraction of eligible patients?

Sources

• Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. NEJM 2025 (REDEFINE-1)
• Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. NEJM 2025 (REDEFINE-2)
• Novo Nordisk FDA NDA submission announcement (December 18, 2025)
• Eli Lilly TRIUMPH-4 topline results (December 2025)

Last updated: March 6, 2026